Candel Therapeutics (CADL) Retained Earnings (2020 - 2023)
Historic Retained Earnings for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to -$125.9 million.
- Candel Therapeutics' Retained Earnings fell 3396.27% to -$125.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$125.9 million, marking a year-over-year decrease of 3396.27%. This contributed to the annual value of -$99.1 million for FY2022, which is 2340.62% down from last year.
- Per Candel Therapeutics' latest filing, its Retained Earnings stood at -$125.9 million for Q3 2023, which was down 3396.27% from -$117.5 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Retained Earnings ranged from a high of -$44.2 million in Q4 2020 and a low of -$125.9 million during Q3 2023
- Over the past 4 years, Candel Therapeutics' median Retained Earnings value was -$85.3 million (recorded in 2022), while the average stood at -$89.4 million.
- In the last 5 years, Candel Therapeutics' Retained Earnings crashed by 8178.22% in 2021 and then tumbled by 1479.41% in 2022.
- Over the past 4 years, Candel Therapeutics' Retained Earnings (Quarter) stood at -$44.2 million in 2020, then crashed by 81.78% to -$80.3 million in 2021, then dropped by 23.41% to -$99.1 million in 2022, then dropped by 27.09% to -$125.9 million in 2023.
- Its last three reported values are -$125.9 million in Q3 2023, -$117.5 million for Q2 2023, and -$107.9 million during Q1 2023.